Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erick Singh

Gastroenterology West Columbia, SC Medical Doctor

NPI 1588862619 CMS profile 1261967

131 Summerplace Dr, West Columbia, SC 29169

Open in the dashboard

General payments

$9,282

554 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erick Singh of West Columbia, SC is reported in the CMS Open Payments database as having received $9,282 across 554 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,117 122
2024 General $2,350 137
2023 General $1,236 81
2022 General $1,337 83
2021 General $647 51
2020 General $267 12
2019 General $1,326 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erick Singh
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Erick Singh were reported at $2,117. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Erick Singh Gastroenterology median Middle half National median
2019 $1,326 $417 $126–$1,100 $163
2020 $267 $224 $74–$624 $114
2021 $647 $352 $106–$1,054 $132
2022 $1,337 $448 $129–$1,270 $149
2023 $1,236 $533 $150–$1,390 $160
2024 $2,350 $605 $160–$1,606 $164
2025 $2,117 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,780 196 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,215 72 payments
  3. Pfizer Inc. $579 38 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $491 25 payments
  5. Merck Sharp & Dohme Corporation $416 19 payments
  6. Janssen Biotech, Inc. $335 25 payments
  7. Ardelyx, Inc. $321 17 payments
  8. Lilly USA, LLC $299 18 payments
  9. QOL Medical, LLC $298 20 payments
  10. Boston Scientific Corporation $231 3 payments
  11. Other $2,318 121 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,218 550 payments
  2. Education $52 3 payments
  3. Consulting Fee $11 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,275 58 payments
  2. XIFAXAN $1,073 63 payments
  3. CREON $547 69 payments
  4. LINZESS $529 74 payments
  5. SKYRIZI Immunology $504 25 payments
  6. XELJANZ $488 32 payments
  7. DIFICID $416 19 payments
  8. MAVYRET $371 27 payments
  9. SKYRIZI Immunology $361 18 payments
  10. IBSRELA $321 17 payments
  11. Other $5,201 287 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,296

Median for Internal Medicine: 777

Drug cost

$697,986

Median for Internal Medicine: $73,373

Branded share of claims

30.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 14 $194,700
Xifaxan Rifaximin Brand 49 $145,718
Linzess Linaclotide Brand 129 $110,626
Creon Lipase/Protease/Amylase Brand 25 $99,742
Zenpep Lipase/Protease/Amylase Brand 11 $26,365
Mesalamine Generic 18 $26,027
Motegrity Prucalopride Succinate Brand 41 $23,497
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 246 $16,297
Colestipol Hcl Generic 126 $9,264
Omeprazole Generic 408 $6,730

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$184,744

Medicare's payments for the services billed

Medicare patients

1,047

Average age 73

Services billed

2,601

616 women, 431 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 34%
Ischemic heart disease 34%
Chronic kidney disease 31%
Depression 28%
Atrial fibrillation 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $244
$244 — —
SKYRIZI
  • AbbVie, Inc. $199
$199 — —
DIFICID
  • Merck Sharp & Dohme Corporation $170
$170 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $85
  • AbbVie, Inc. $67
$152 129 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $145
$145 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

554 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record